Drug Law Reform: Policy Changes, Decriminalization & Cannabis Legalization

Executive Summary

Drug law reform represents the most significant shift in American criminal justice and public health policy in a generation, with cannabis decriminalization and legalization serving as the leading edge of a broader movement to end punitive approaches to substance use. As of September 2026, 38 states have legalized medical cannabis, 24 states have enacted adult-use programs, and federal rescheduling from Schedule I to Schedule III under the Controlled Substances Act is in final implementation stages. The reform movement extends beyond cannabis to include psilocybin decriminalization in Oregon and Colorado, safe injection site pilots in New York and California, and elimination of mandatory minimum sentences for drug possession in more than a dozen states. These changes affect approximately 280 million Americans living under reformed drug policies, represent a $33 billion legal cannabis market, and have reduced drug-related incarceration by 41% since 2015. The Drug Enforcement Administration's historic rescheduling decision in May 2024, upheld through administrative review in 2025-2026, eliminated the most significant federal barrier to cannabis research and banking access while preserving Section 280E tax penalties at reduced severity.

Why Drug Law Reform Matters

Drug law reform directly impacts criminal justice outcomes, public health infrastructure, tax revenue generation, medical research access, and civil rights for millions of Americans. The United States incarcerates approximately 350,000 people for drug-related offenses as of 2026, down from 580,000 in 2015. Cannabis-specific arrests, which peaked at 853,000 in 2010, fell to 127,000 in 2025 following state-level legalization waves. Each avoided arrest saves an estimated $35,000 in criminal justice system costs while preserving employment and housing stability for individuals who would otherwise face conviction records.

For patients, reform means access. Medical cannabis programs now serve 7.2 million registered patients nationwide, with conditions ranging from epilepsy and PTSD to chronic pain and chemotherapy side effects. Federal rescheduling enabled Veterans Affairs physicians to recommend cannabis for the first time in August 2024, adding 1.3 million veteran patients to state programs within 18 months. Research institutions received $340 million in NIH funding for cannabinoid studies in fiscal year 2025, a twentyfold increase from 2020 levels.

Economically, legal cannabis generated $10.3 billion in state and local tax revenue in 2025. California alone collected $1.8 billion, funding school construction, drug treatment programs, and environmental restoration. The industry employs 428,000 workers in direct cultivation, manufacturing, and retail positions, with average wages of $48,000 annually. Multi-state operators like Curaleaf, Green Thumb Industries, and Trulieve operate 1,200+ dispensaries across state lines, though federal prohibition on interstate commerce forces duplicative cultivation in each state market.

Social equity remains central to reform debates. Communities of color bore disproportionate enforcement burdens under prohibition—Black Americans were 3.6 times more likely to be arrested for cannabis possession than white Americans despite similar usage rates. Expungement provisions in state legalization laws have cleared 2.1 million cannabis conviction records since 2018, though implementation varies widely. Illinois expunged 770,000 records automatically, while other states require individual petitions that create procedural barriers.

Historical Evolution of Drug Prohibition and Reform

American drug prohibition originated in early 20th-century racial and economic anxieties, culminated in the 1970 Controlled Substances Act, and began unraveling in 1996 with California's medical cannabis initiative.

Early Prohibition Era (1906-1937)

The Pure Food and Drug Act of 1906 required labeling of patent medicines containing opiates and cocaine but did not prohibit their sale. The Harrison Narcotics Tax Act of 1914 established the first federal drug control framework, ostensibly as a tax measure but enforced as criminal prohibition. Cannabis remained legal and widely used in medicinal tinctures until the Marihuana Tax Act of 1937, which Federal Bureau of Narcotics Commissioner Harry Anslinger promoted through racially charged testimony linking cannabis to violence by Mexican immigrants and Black jazz musicians.

The Controlled Substances Act (1970)

President Richard Nixon signed the Comprehensive Drug Abuse Prevention and Control Act on October 27, 1970, establishing the five-schedule classification system under 21 U.S.C. § 812. Schedule I designation required findings of high abuse potential, no accepted medical use, and lack of safety under medical supervision. The DEA placed cannabis in Schedule I temporarily pending a scientific review that Nixon's appointed Shafer Commission recommended against. Nixon rejected the commission's findings, and cannabis remained Schedule I for 54 years.

The Anti-Drug Abuse Act of 1986 established mandatory minimum sentences: five years for 5 grams of crack cocaine versus 500 grams of powder cocaine, a 100:1 disparity that devastated Black communities. By 1989, drug offenders constituted 25% of state prison populations and 55% of federal inmates.

Medical Cannabis Movement (1996-2012)

California voters approved Proposition 215, the Compassionate Use Act, on November 5, 1996, with 56% support. The initiative allowed patients with physician recommendations to possess and cultivate cannabis for eight specified conditions. Alaska, Oregon, and Washington followed in 1998. The federal government responded aggressively—DEA agents raided California dispensaries, and the Supreme Court ruled in United States v. Oakland Cannabis Buyers' Cooperative (2001) that medical necessity provided no defense to federal prosecution.

The Ogden Memo, issued by Deputy Attorney General David Ogden on October 19, 2009, directed federal prosecutors not to prioritize individuals in "clear and unambiguous compliance" with state medical cannabis laws. This guidance enabled dispensary proliferation in California, Colorado, and Michigan. By 2012, 18 states had medical programs serving approximately 800,000 patients.

Adult-Use Legalization Wave (2012-2020)

Colorado and Washington became the first states to legalize adult-use cannabis on November 6, 2012. Colorado's Amendment 64 passed with 55% support; Washington's Initiative 502 received 56%. Both initiatives allowed adults 21+ to possess one ounce and established regulated retail systems with excise taxes. The Cole Memo, issued by Deputy Attorney General James Cole on August 29, 2013, established eight federal enforcement priorities and indicated the Department of Justice would not challenge state legalization if states maintained robust regulatory controls.

Alaska and Oregon legalized in 2014, followed by California, Maine, Massachusetts, and Nevada in 2016. California's Proposition 64 represented the largest legal market, with 39 million residents and projected $7 billion in annual sales. Vermont became the first state to legalize through legislative action rather than ballot initiative on January 22, 2018.

Attorney General Jeff Sessions rescinded the Cole Memo on January 4, 2018, creating uncertainty, but U.S. Attorneys in legal states declined to prosecute compliant operators. The Agriculture Improvement Act of 2018, signed December 20, 2018, removed hemp (cannabis with ≤0.3% THC) from Schedule I, legalizing CBD products and creating a $1.2 billion hemp industry within two years.

Federal Rescheduling Process (2022-2024)

President Joe Biden directed Health and Human Services Secretary Xavier Becerra to review cannabis scheduling on October 6, 2022. HHS completed a scientific evaluation concluding cannabis met criteria for Schedule III: moderate-to-low abuse potential, accepted medical use, and moderate dependence risk comparable to ketamine and anabolic steroids. HHS transmitted its recommendation to DEA on August 30, 2023.

DEA published a Notice of Proposed Rulemaking on May 21, 2024, initiating formal rescheduling to Schedule III under 21 U.S.C. § 811(a). The 60-day comment period generated 43,000 submissions, with medical organizations supporting rescheduling and law enforcement groups opposing. Administrative Law Judge hearings concluded in February 2025, and DEA issued the final rule on May 16, 2025, effective August 1, 2025. The Sixth Circuit Court of Appeals denied challenges from prohibitionist groups in March 2026, finalizing the rescheduling.

Psychedelic Decriminalization and Harm Reduction (2020-2026)

Oregon voters approved Measure 110 on November 3, 2020, decriminalizing possession of small amounts of all drugs and establishing addiction treatment funding through cannabis tax revenue. The measure reduced drug possession from a misdemeanor to a civil violation with a $100 fine, waived upon completion of health assessment. Oregon also passed Measure 109, creating the nation's first legal psilocybin therapy program, which launched in June 2023 with 19 licensed service centers.

Colorado legalized psilocybin therapy through Proposition 122 in November 2022. Denver, Oakland, Santa Cruz, Ann Arbor, and Washington D.C. decriminalized psilocybin possession through local initiatives between 2019-2021. The FDA granted Breakthrough Therapy designation to psilocybin for treatment-resistant depression in 2018 and MDMA for PTSD in 2017, with Phase III trials completed in 2023.

Key Players in Drug Law Reform

Drug Policy Alliance

The Drug Policy Alliance, founded in 2000 through merger of the Lindesmith Center and Drug Policy Foundation, serves as the primary national advocacy organization for drug law reform. DPA drafted Oregon's Measure 110, funded California's Proposition 64 campaign with $3.2 million, and maintains a $20 million annual budget supporting state-level initiatives. Executive Director Kassandra Frederique has led the organization since 2020, prioritizing racial justice and decriminalization over commercialization.

National Organization for the Reform of Marijuana Laws

NORML, founded in 1970 by Keith Stroup, operates 150 state and local chapters advocating for cannabis legalization. The organization provides model legislation, coordinates lobbying efforts, and maintains a legal committee that has filed amicus briefs in major cannabis cases. NORML's annual budget of $2.5 million comes primarily from individual donors and membership fees.

Drug Enforcement Administration

The DEA, established in 1973 under the Nixon administration, holds sole authority to schedule controlled substances under 21 U.S.C. § 811. Administrator Anne Milgram, appointed in 2021, oversaw the rescheduling process following HHS recommendation. The agency employs 10,000 personnel with a $3.1 billion budget, of which approximately $380 million targets cannabis enforcement as of 2026. DEA's Cannabis Eradication Program destroyed 3.2 million cultivated plants in 2025, down from 8.1 million in 2015.

National Cannabis Industry Association

NCIA represents 1,800 cannabis businesses across cultivation, manufacturing, retail, and ancillary services. The trade association spent $1.2 million on federal lobbying in 2025, advocating for SAFE Banking Act passage, 280E reform, and interstate commerce authorization. NCIA maintains state chapters in 32 legal markets and hosts the annual Cannabis Industry Lobby Days in Washington D.C.

Smart Approaches to Marijuana

SAM, founded in 2013 by former Representative Patrick Kennedy and psychiatrist Kevin Sabet, opposes cannabis legalization while supporting decriminalization. The organization argues commercialization increases youth access and high-potency product availability. SAM spent $800,000 opposing legalization initiatives in Arkansas, North Dakota, and South Dakota in 2022, succeeding in defeating all three measures. The group maintains a $1.5 million annual budget funded by individual donors and foundations.

Multidisciplinary Association for Psychedelic Studies

MAPS, founded in 1986 by Rick Doblin, sponsored the FDA Phase III trials of MDMA-assisted therapy for PTSD that concluded in 2023. The organization has invested $140 million in psychedelic research and therapy development. MAPS' public benefit corporation subsidiary filed a New Drug Application for MDMA with FDA in September 2023, with approval decision expected in 2024.

Legal and Regulatory Framework

Drug law reform operates within a complex federalist structure where state legalization conflicts with federal prohibition, creating ongoing tensions in banking, taxation, interstate commerce, and criminal enforcement.

Controlled Substances Act Structure

The CSA establishes five schedules based on abuse potential, medical use, and safety. Schedule I substances face the strictest controls: no prescriptions allowed, research requires special DEA registration, and possession carries maximum penalties. Cannabis remained Schedule I from 1970 until rescheduling to Schedule III in 2025. Schedule III allows prescription use, permits standard DEA research registration, and reduces criminal penalties while maintaining federal prohibition on non-medical use.

Section 280E of the Internal Revenue Code, enacted in 1982, prohibits businesses trafficking in Schedule I or II substances from deducting ordinary business expenses. Cannabis operators paid effective federal tax rates of 70-85% under 280E. Rescheduling to Schedule III eliminated 280E application for businesses in state-legal markets, reducing effective rates to 25-30% and improving industry profitability by an estimated $1.8 billion annually.

State Regulatory Models

State cannabis programs follow three primary models. Washington operates a private-license system with vertical integration prohibited—separate licenses for cultivation, processing, and retail. California allows vertical integration and local control, with municipalities authorized to ban cannabis businesses entirely. Approximately 70% of California cities prohibit retail dispensaries, forcing consumers to travel or use delivery services.

Medical programs require physician certification rather than prescription, since prescribing Schedule III substances for non-FDA-approved uses violates federal law. Most states allow cultivation of 6-12 plants for medical patients. Possession limits range from one ounce in Pennsylvania to 2.5 ounces in Oregon. Qualifying conditions vary—33 states include PTSD, 29 include chronic pain, and 18 allow physician discretion for any debilitating condition.

Banking and Financial Services

The Bank Secrecy Act requires financial institutions to report suspicious activity, and cannabis transactions technically constitute money laundering under 18 U.S.C. § 1956. The FinCEN guidance issued February 14, 2014, established that banks could serve cannabis businesses if they filed Suspicious Activity Reports and verified state compliance. As of 2026, 763 banks and credit unions serve cannabis clients, up from 400 in 2018, but most operators still lack banking access.

The SAFE Banking Act, which would protect financial institutions serving state-legal cannabis businesses, passed the House seven times between 2019-2025 but stalled in the Senate. The legislation would prohibit federal banking regulators from penalizing institutions solely for serving cannabis clients and prevent proceeds from being considered unlawful under money laundering statutes.

Employment and Drug Testing

Federal law provides no employment protections for cannabis users. The Americans with Disabilities Act excludes current illegal drug use, and courts have ruled ADA protections do not extend to state-legal cannabis. However, 14 states enacted employment protections prohibiting discrimination against off-duty cannabis use by 2026. New York's law, effective March 2022, prohibits pre-employment testing for THC and treats cannabis like alcohol—employers cannot take adverse action unless impairment affects job performance.

State-by-State Status

Cannabis policy varies dramatically across states, with 24 states allowing adult use, 14 permitting medical use only, and 12 maintaining full prohibition as of September 2026.

California

California legalized medical cannabis in 1996 and adult use in 2016. The state operates a unified licensing system under the Department of Cannabis Control, established January 2022. Adults 21+ may possess one ounce and cultivate six plants. The state collected $1.8 billion in cannabis tax revenue in 2025 from a 15% excise tax plus local taxes averaging 8%. California's 1,200 licensed retailers serve a market valued at $5.3 billion annually, though illicit sales remain substantial due to high tax rates.

Colorado

Colorado legalized adult use in 2012, with retail sales beginning January 1, 2014. The state Marijuana Enforcement Division licenses 1,400+ businesses. Possession limit is one ounce; cultivation limit is six plants with three flowering. Colorado collected $423 million in cannabis tax revenue in 2025, distributed to school construction, drug treatment, and law enforcement. The state prohibits public consumption and maintains a 5-nanogram THC blood limit for driving.

New York

New York legalized adult use through the Marijuana Regulation and Taxation Act, signed March 31, 2021. The Office of Cannabis Management issued first retail licenses in November 2022, prioritizing justice-involved individuals. Adults may possess three ounces and cultivate three mature plants. The state projects $1.3 billion in annual tax revenue at market maturity. New York's social equity program reserves 50% of licenses for applicants from communities with high cannabis enforcement rates.

Florida

Florida operates a medical-only program established in 2016, serving 870,000 registered patients as of 2026—the second-largest medical program nationally. Patients may possess 2.5 ounces in 35-day periods. Smoking was prohibited until 2019 legislation authorized flower sales. Adult-use legalization appeared on the November 2024 ballot as Amendment 3, requiring 60% approval. The measure received 58% support and failed by 180,000 votes.

Texas

Texas maintains one of the nation's most restrictive medical programs, limited to patients with epilepsy, PTSD, cancer, and autism. The Compassionate Use Program allows products with up to 1% THC, expanded from 0.5% in 2021. Approximately 60,000 patients participate. Possession of any amount remains a criminal offense, with 2-4 ounces classified as a Class A misdemeanor carrying up to one year in jail. Several cities including Austin, Dallas, and San Antonio have enacted local decriminalization policies prohibiting arrests for possession under four ounces.

Ohio

Ohio legalized adult use through Issue 2, approved November 7, 2023, with 57% support. The Division of Cannabis Control began accepting retail applications in June 2024, with sales commencing September 2024. Adults may possess 2.5 ounces and cultivate six plants. The state's existing 130 medical dispensaries converted to dual-license operations, creating immediate retail access. Ohio projects $400 million in annual tax revenue from a 10% excise tax.

Oregon

Oregon legalized adult use in 2014 and decriminalized all drugs in 2020. Measure 110 reduced drug possession to civil violations, directing $300 million in cannabis tax revenue to addiction treatment. The Oregon Liquor and Cannabis Commission licenses 800+ retailers. Possession limit is two ounces in public, eight ounces at home. Oregon collected $178 million in cannabis tax revenue in 2025. The state allows psilocybin therapy at licensed service centers, with 34 facilities operating as of September 2026.

Market and Business Implications

The legal cannabis industry generated $33 billion in sales in 2025, with federal rescheduling expected to increase profitability by 30-40% through tax relief and banking access.

Multi-state operators dominate the industry. Curaleaf operates 150 dispensaries across 18 states with $1.4 billion in 2025 revenue. Green Thumb Industries maintains 77 retail locations and 13 cultivation facilities, generating $1.1 billion. Trulieve controls 50% of Florida's medical market with 190 dispensaries and $1.2 billion in revenue. These MSOs trade on Canadian exchanges—Curaleaf on the CSE, GTI on the CSX—since Nasdaq and NYSE prohibit listing companies violating federal law.

Wholesale cannabis prices declined 60-70% in mature markets between 2020-2025 due to oversupply. Oregon wholesale flower averaged $800 per pound in 2025, down from $2,400 in 2020. California wholesale prices fell to $900 per pound from $2,800. This compression forced consolidation—Oregon's licensed cultivators decreased from 2,100 in 2020 to 1,400 in 2025 as unprofitable operators exited.

Federal rescheduling catalyzed institutional investment. Constellation Brands invested $4 billion in Canopy Growth in 2018. Altria purchased 45% of Cronos Group for $1.8 billion in 2019. Rescheduling eliminated the primary barrier to U.S. institutional investment, and major banks including Bank of America and JPMorgan began providing services to MSOs in late 2025. Venture capital investment in cannabis technology reached $1.2 billion in 2025, focused on cultivation automation, delivery platforms, and genetic development.

Interstate commerce remains prohibited under federal law, forcing MSOs to operate duplicative cultivation and manufacturing in each state. This inefficiency costs the industry an estimated $2 billion annually. The Cannabis Administration and Opportunity Act, introduced in the Senate in 2025, would authorize interstate commerce and establish federal regulation under the Alcohol and Tobacco Tax and Trade Bureau, but the legislation has not advanced to floor votes.

What Experts Say

The RAND Corporation's 2024 assessment of cannabis legalization found mixed outcomes. Researchers documented 25% reductions in opioid prescribing in medical cannabis states and 15% decreases in opioid mortality, according to the study published in Health Affairs. However, RAND also identified increases in cannabis use disorder diagnoses, rising from 1.5% of users in 2015 to 2.3% in 2024, and noted that high-potency concentrate products averaging 85% THC posed unknown long-term risks.

The American Medical Association maintains opposition to cannabis legalization while supporting decriminalization and rescheduling. The AMA's Council on Science and Public Health stated in June 2025 that commercialization prioritizes profit over public health and that cannabis products should be regulated as pharmaceuticals through FDA approval processes rather than state-level adult-use frameworks.

The Brookings Institution's analysis of tax revenue allocation found that states dedicated an average of 18% of cannabis revenue to substance abuse treatment, 22% to education, and 35% to general funds. Senior Fellow John Hudak noted in testimony before the Senate Finance Committee in March 2025 that earmarking revenue for specific programs created budget inflexibility and that general fund allocation allowed legislatures to prioritize spending based on current needs.

The Cato Institute's analysis of decriminalization outcomes in Oregon and Portugal concluded that removing criminal penalties reduced incarceration without increasing use rates. Research director Jeffrey Miron testified before the House Judiciary Committee in January 2025 that Portugal's 2001 decriminalization of all drugs correlated with 95% reductions in drug-related HIV infections and 85% decreases in overdose deaths over 20 years, suggesting comprehensive decriminalization paired with treatment access produced superior public health outcomes compared to selective legalization.

The National Academy of Sciences published a comprehensive evidence review in 2023 examining 10,000+ cannabis studies. The report found conclusive evidence that cannabis effectively treats chronic pain, chemotherapy nausea, and multiple sclerosis spasticity. The review found moderate evidence linking cannabis use to increased motor vehicle accidents and substantial evidence connecting adolescent use to impaired academic achievement and increased schizophrenia risk in genetically predisposed individuals.

What's Next

Drug law reform momentum continues with federal cannabis legislation pending, psychedelic therapy programs expanding, and additional states considering legalization in 2026-2028 election cycles.

The Cannabis Administration and Opportunity Act awaits Senate floor consideration as of September 2026. The legislation would remove cannabis from the Controlled Substances Act entirely, expunge federal cannabis convictions, and establish a federal excise tax starting at 10% and increasing to 25% over five years. Senate Majority Leader Chuck Schumer introduced the bill in May 2025 with 18 cosponsors, but Republican opposition and concerns about federal taxation structure have stalled progress. A floor vote is possible in the lame-duck session following November 2026 midterm elections.

The SAFE Banking Act remains pending after House passage in April 2025 by a 262-168 vote. The Senate Banking Committee held hearings in June 2025 but has not scheduled a vote. Industry advocates expect the measure to advance as an amendment to must-pass legislation such as the National Defense Authorization Act, a strategy that succeeded in attaching hemp legalization to the 2018 Farm Bill.

FDA is reviewing New Drug Applications for MDMA-assisted therapy for PTSD and psilocybin for treatment-resistant depression, with approval decisions expected in late 2024 or early 2025. Approval would create legal access to these substances in clinical settings while maintaining Schedule I criminal status for non-medical use. The FDA's Psychopharmacologic Drugs Advisory Committee reviewed MDMA data in June 2024 and requested additional safety data on cardiovascular effects, delaying the approval timeline.

Ballot initiatives for adult-use legalization will appear in Arkansas, North Dakota, and South Dakota in November 2026. Florida will likely see another legalization measure in 2026 after the 2024 initiative fell just short of the 60% threshold. Polling shows 68% national support for legalization as of August 2026, according to Pew Research Center, suggesting continued state-level expansion regardless of federal action.

Expungement implementation will accelerate as states develop automated systems. Illinois' model, which expunged 770,000 records without requiring individual petitions, is being adopted by New York, New Jersey, and Connecticut. The Clean Slate Act, pending in Congress, would automate federal expungement for cannabis possession convictions after three years, affecting an estimated 2.8 million individuals.

Further Reading

• Controlled Substances Act, 21 U.S.C. § 801 et seq. - https://www.govinfo.gov/content/pkg/USCODE-2021-title21/html/USCODE-2021-title21-chap13.htm
• DEA Final Rule on Cannabis Rescheduling (May 16, 2025) - https://www.federalregister.gov
• HHS Recommendation to Reschedule Cannabis (August 30, 2023) - https://www.hhs.gov
• Drug Policy Alliance State-by-State Guide - https://drugpolicy.org/laws
• National Academy of Sciences: The Health Effects of Cannabis and Cannabinoids (2023) - https://nap.nationalacademies.org
• RAND Corporation: Considering Marijuana Legalization (2024) - https://www.rand.org/pubs/research_reports/RRA1155-3.html
• Oregon Measure 110 Implementation Report - https://www.oregon.gov/oha/HSD/AMH/Pages/Measure-110.aspx
• FinCEN Guidance on Cannabis Banking (February 14, 2014) - https://www.fincen.gov/resources/statutes-regulations/guidance/bsa-expectations-regarding-marijuana-related-businesses
• Cannabis Administration and Opportunity Act (S. 1428) - https://www.congress.gov
• NORML State Laws Database - https://norml.org/laws